Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Profit After Tax for 13 consecutive years, with -$108.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 11.93% year-over-year to -$108.0 million, compared with a TTM value of -$412.8 million through Dec 2025, down 161.27%, and an annual FY2025 reading of -$412.8 million, down 161.27% over the prior year.
  • Profit After Tax was -$108.0 million for Q4 2025 at Agios Pharmaceuticals, down from -$103.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $1.9 billion in Q1 2021 and bottomed at -$112.0 million in Q2 2025.
  • Average Profit After Tax over 5 years is $162.0 million, with a median of -$89.0 million recorded in 2021.
  • The sharpest move saw Profit After Tax soared 4756.01% in 2021, then plummeted 362.66% in 2023.
  • Year by year, Profit After Tax stood at $1.9 billion in 2021, then crashed by 98.04% to $36.5 million in 2022, then tumbled by 362.66% to -$95.9 million in 2023, then fell by 0.61% to -$96.5 million in 2024, then fell by 11.93% to -$108.0 million in 2025.
  • Business Quant data shows Profit After Tax for AGIO at -$108.0 million in Q4 2025, -$103.4 million in Q3 2025, and -$112.0 million in Q2 2025.